Video

Updated Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Advanced Endometrial Cancer: Study 309/KEYNOTE-775

Author(s):

Domenica Lorusso, MD, PhD

Dr Domenica Lorusso reviews data updates from KEYNOTE-775 that were recently presented at the European Society for Medical Oncology (ESMO) Congress 2022.

Related Videos
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Amin Nassar, MD
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus
Hye Sook Chon, MD, gynecologic oncologist, Gynecologic Oncology Program, Moffitt Cancer Center
John Paul Diaz, MD
Keiichi Fujiwara, MD, PhD, Saitama Medical University International Medical Center
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Jefferson DeKloe, BS, medical student, Western Michigan University; research fellow, Thomas Jefferson University
May 23rd 2024

HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Rebecca Porter, MD, PhD, of Dana-Farber Cancer Institute
May 20th 2024

Mirvetuximab Soravtansine Plus Pembrolizumab Generates Reponses in pMMR FRα+ Serous Endometrial Cancer

US FDA
May 15th 2024

FDA Approves HPV Self-Collection Test for Cervical Cancer